Retrospective analysis of the safety and efficacy of vandetanib as systemic treatment for patients with advanced and progressive medullary thyroid cancer (MTC)

被引：0
|
作者：
Capdevila, Jaume
Martinez-Trufero, Javier
Dalmau, Elsa
Alvarez-Escala, Cristina
Beltran, Miguel
Duran, Manuel
Gallegos, Isabel
Luis Manzano, Jose
Mesla, Ricard
Pajares, Isabel
Fuentes Pradera, Jose
Grau, Juan J.
Reig, Oscar
Manuel Trigo, Jose
Grande, Enrique
机构：
[1] Vall dHebron Univ Hosp, Barcelona, Spain
[2] Hosp Miguel Servet, Zaragoza, Spain
[3] Univ Autonoma Barcelona, Corp Sanitaria Univ Parc Tauli, Sabadell, Spain
[4] La Paz Univ Hosp, Dept Endocrinol, Madrid, Spain
[5] Hosp Univ Josep Trueta, Inst Catala Oncol, Girona, Spain
[6] Rey Juan Carlos Univ Hosp, Madrid, Spain
[7] Hosp Gen Segovia, Segovia, Spain
[8] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain
[9] Catalan Inst Oncol, Barcelona, Spain
[10] Hosp Univ Miguel Servet, Zaragoza, Spain
[11] Hosp Univ Virgen de Valme, Seville, Spain
[12] Hosp Clin Barcelona, Barcelona, Spain
[13] Hosp Univ Virgen de la Victoria, Malaga, Spain
[14] Hosp Univ Ramon y Cajal, Dept Med Oncol, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17016
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The safety of vandetanib for the treatment of thyroid cancer
    Tsang, Venessa H. M.
    Robinson, Bruce G.
    Learoyd, Diana L.
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (08) : 1107 - 1113
  • [22] Vandetanib—a new therapeutic option in advanced medullary thyroid cancer
    Linda Koch
    Nature Reviews Endocrinology, 2012, 8 (1) : 1 - 1
  • [23] Vandetanib: A Guide to Its Use in Advanced Medullary Thyroid Cancer
    Keating, Gillian M.
    Lyseng-Williamson, Katherine A.
    Frampton, James E.
    BIODRUGS, 2012, 26 (06) : 431 - 435
  • [24] Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer
    Bastholt, Lars
    Kreissl, Michael C.
    Fuehrer, Dagmar
    Maia, Ana L.
    Locati, Laura D.
    Maciel, Lea
    Wu, Yi
    Heller, Kevin N.
    Webster, Alan
    Elisei, Rossella
    EUROPEAN THYROID JOURNAL, 2016, 5 (03) : 187 - 194
  • [25] Vandetanib: A Guide to Its Use in Advanced Medullary Thyroid Cancer
    Gillian M. Keating
    Katherine A. Lyseng-Williamson
    James E. Frampton
    BioDrugs, 2012, 26 (6) : 431 - 435
  • [26] Vandetanib: A novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer
    Ton, GiangThy N.
    Banaszynski, Megan E.
    Kolesar, Jill M.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (10) : 849 - 855
  • [27] Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer
    Helton Estrela Ramos
    Fabio Hecht
    Amandine Berdelou
    Isabelle Borget
    Sophie Leboulleux
    Eric Baudin
    Martin Schlumberger
    Endocrine, 2021, 71 : 434 - 442
  • [28] Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer
    Ramos, Helton Estrela
    Hecht, Fabio
    Berdelou, Amandine
    Borget, Isabelle
    Leboulleux, Sophie
    Baudin, Eric
    Schlumberger, Martin
    ENDOCRINE, 2021, 71 (02) : 434 - 442
  • [29] Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
    Robinson, Bruce G.
    Paz-Ares, Luis
    Krebs, Annetta
    Vasselli, James
    Haddad, Robert
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (06): : 2664 - 2671
  • [30] Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma
    Durante, Cosimo
    Paciaroni, Alessandra
    Plasmati, Katia
    Trulli, Fabiana
    Filetti, Sebastiano
    ENDOCRINE, 2013, 44 (02) : 334 - 342
12345